Press
Releases

Date Title and Summary Additional Formats
Nov 29, 2022
HOUSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced the pricing of its underwritten public offering of approximately 24,228,719 shares of its common stock for gross
Nov 28, 2022
HOUSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it has commenced an underwritten public offering of its common stock.
Nov 14, 2022
Presented early data highlighting first successful objective clinical response using non-viral Sleeping Beauty TCR-T cell therapy in solid tumors at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (CICON) Actively enrolling patients in TCR-T Library Phase 1/2 trial at the
Nov 08, 2022
HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the third quarter ended September 30, 2022 on Monday, November 14, 2022, before the open of U.S. markets.
Nov 07, 2022
Data supports high-throughput screening process to identify neoantigen-reactive TCRs Exclusive ownership of discovered KRAS mutation-reactive TCRs hunTR enables expansion of the Company’s hotspot mutation targeted TCR library HOUSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc.
Sep 21, 2022
First patient achieved a confirmed partial response with 51.2% tumor regression with TCR-T cell persistence ongoing at 3 months post infusion Sleeping Beauty TCR-T cell therapy had a manageable safety profile with no dose limiting toxicities observed Data to be presented on Friday, September 30 at
Sep 07, 2022
HOUSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research & Development
Sep 06, 2022
First patient dosed achieved a confirmed objective partial response Second patient dosed at second dose level; cleared 28-day safety window Data to be presented on Friday, September 30 at 8:30am ET in a proffered presentation at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference
Aug 24, 2022
HOUSTON, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it has been accepted to present a proffered talk at the CRI-ENCI-AACR Sixth International Cancer
Aug 15, 2022
Advancing TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications; plan to present early data in 3Q 2022 at a scientific conference; moving ahead with second dose level Extended Cooperative Research and Development Agreement for development of